As per the extension, Novartis will fund research at GenVec through January 2013 to support its hearing loss and balance disorders program.
GenVec has entered into a worldwide licensing and collaboration agreement with Novartis to discover and develop novel treatments for hearing loss and balance disorders, in January 2010.
In August 2010, GenVec entered into an additional agreement with Novartis, to manufacture clinical trial material for up to two lead product candidates for this program.
GenVec research vice president Douglas Brough said GenVec has worked closely with Novartis for the past two years to move the program forward.
"This extension will allow GenVec to continue supporting this important effort," Brough added.